Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) - Epidemiology Forecast - 2034
Description
Key Highlights
DelveInsight research indicates that in 2024, there were around 180,000 diagnosed prevalent cases of PH-ILD across the 7MM, which are expected to increase by 2034.
In the US, there were over 80,000 diagnosed prevalent cases of PH-ILD in 2024, accounting for approximately 45% of all diagnosed cases across the 7MM.
The rise in PH-ILD cases in the 7MM is driven by improved diagnostic tools, and a growing aging population. Broader screening among patients with Interstitial Lung Diseases (ILD) and advancements in imaging and pulmonary testing also contribute. Additionally, evolving clinical guidelines promote earlier detection, leading to higher reported prevalence rates over time.
Japan accounted for 16% of the diagnosed PH-ILD cases across the 7MM. The number of cases is expected to rise due to the country's aging population, which increases the risk of ILD and related complications.
In Germany, PH-ILD prevalence was slightly higher in males with nearly 8,700 cases as compared to 6,300 females in 2024, with the gap expected to widen by 2034.
Early and accurate diagnosis of PH-ILD remains challenging due to overlapping symptoms with other respiratory conditions and the absence of specific diagnostic tools, often leading to delays in identification and increased risk of disease progression.
DelveInsight’s “Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) –Epidemiology Forecast – 2034” report delivers an in-depth understanding of PH-ILD, historical and forecasted epidemiology trends in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
The PH-ILD report focuses on the epidemiological landscape, providing detailed insights into current and forecasted diagnosed prevalence across the 7MM from 2020 to 2034. It highlights geographic variations, demographic trends, and factors influencing disease burden to support strategic planning and resource allocation.
Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Disease Understanding
Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Overview
PH-ILD is a chronic, progressive condition that develops as a complication of various ILDs, including idiopathic pulmonary fibrosis (IPF), connective tissue disease (CTD), and hypersensitivity pneumonitis. It is marked by elevated pressure in the pulmonary arteries due to lung scarring and vascular remodeling. This places increased strain on the heart and lungs, leading to symptoms such as worsening shortness of breath, fatigue, and reduced exercise capacity. Over time, these symptoms significantly limit daily activities and diminish quality of life. PH-ILD is often underdiagnosed or diagnosed late, as its symptoms overlap with those of the underlying ILD.
Further details related to country-based variations are provided in the report…
Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Diagnosis
Diagnosing PH-ILD is challenging due to overlapping symptom PH-ILD with underlying ILD. Suspicion should arise in ILD patients with unexplained worsening dyspnea or reduced exercise capacity. Key tools include echocardiography for initial screening and pulmonary function tests showing a disproportionate drop in Diffusing Capacity for Carbon Monoxide (DLCO). High-resolution Computed Tomography (CT) aids in assessing lung fibrosis, while right heart catheterization (RHC) remains the gold standard for confirming pulmonary hypertension. Early, accurate diagnosis through routine monitoring in high-risk ILD patients is crucial for timely intervention and improved outcomes.
Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Epidemiology
For the purpose of designing the patient-based model for PH-ILD, the PH-ILD epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by total diagnosed prevalent cases of ILD, type-specific diagnosed prevalent cases of ILD, type-specific diagnosed prevalent cases of PH-ILD, total diagnosed prevalent cases of PH-ILD, and gender-specific diagnosed prevalent cases of PH-ILD in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan from 2020 to 2034.
In 2024, approximately 1.1 million diagnosed prevalent cases of ILD were reported across the 7MM. This rising burden is largely attributed to improved disease recognition, broader use of high-resolution imaging, and increased awareness among physicians and specialists.
In the US, among the type-specific diagnosed prevalent cases of ILD, idiopathic pulmonary fibrosis (IPF)-associated ILD accounted for the highest number, with nearly 112,000 reported cases in 2024.
In the UK, among the type-specific diagnosed prevalent cases of PH-ILD, sarcoidosis-associated cases were the most common, with approximately 4,000 reported cases in 2024.
In 2024, nearly 70,000 people in the EU4 and UK were living with diagnosed PH-ILD, underscoring a substantial and growing regional disease burden.
In 2024, diagnosed PH-ILD prevalence showed a slightly higher burden in males, with approximately 42,000 cases compared to 39,000 in females in the US. This gender gap is expected to widen by 2034, highlighting potential differences in disease susceptibility or progression.
In 2024, IPF accounted for the largest share of PH-ILD cases in Japan at 21%, while hypersensitivity pneumonitis represented just 1%, underscoring notable variation in subtype distribution and the need for tailored diagnostic and treatment strategies.
In Japan, over 28,000 diagnosed prevalent cases of PH-ILD were reported in 2024, with the numbers projected to increase by 2034, indicating a rising disease burden.
KOL Views
To keep up with current innovation, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts contacted for insights on PH-ILD evolving disease landscape along with challenges related to accessibility, including Medical/scientific writers, Medical Professionals, Professors, Directors, and others.
DelveInsight’s analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Centers like the Baylor College of Medicine and Methodist Hospital, US; University of Minnesota, US; University of Freiburg, Germany; Hôpital St Louis, France; University of Siena, Italy; University of Valencia, Spain; University Forvie Site, UK; Jichi Medical University, Japan; and Chiba University, Japan; among others, were contacted. Their opinion helps understand and validate current disease prevalence, gender involved with the disease, diagnosis rate, and diagnostic criteria.
Physician’s View
As per the KOLs from the US, PH-ILD care faces significant challenges, as timely diagnosis remains limited despite rising prevalence. Overlapping symptoms with other ILDs often contribute to delayed recognition, resulting in patients being identified only at more advanced stages of the disease.
As per the KOLs from the Germany, PH-ILD is characterized by complex vascular remodeling and fibrotic processes, which contribute to disease progression and symptom severity. These underlying mechanisms highlight the need for deeper understanding and innovative approaches to better address the biological drivers of the condition.
As per the KOLs from Japan, The growing burden of PH-ILD, particularly among aging ILD populations, is compounded by the disease’s heterogeneity and complexity. The absence of standardized clinical approaches adds to the challenges, highlighting persistent gaps in real-world patient management and care strategies.
Scope of the Report
The report covers a segment of key events, an executive summary, and a descriptive overview of PH-ILD, explaining its causes, signs and symptom PH-ILD and pathogenesis.
Comprehensive insight into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and diagnostic guidelines have been provided.
The report provides an edge for understanding trends, expert insights/KOL views, and patient journeys in the 7MM.
A detailed review of current challenges in establishing the diagnosis.
Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Report Insights
Patient Population
Country-wise Epidemiology Distribution
Total Diagnosed Prevalent Cases of ILD
Type-specific Diagnosed Prevalent Cases of ILD
Type-specific Diagnosed Prevalent Cases of PH-ILD
Total Diagnosed Prevalent Cases of PH-ILD
Gender-specific Diagnosed Prevalent Cases of PH-ILD
Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Report Key Strengths
10 years Forecast
The 7MM Coverage
PH-ILD Epidemiology Segmentation
Key Questions
Epidemiology Insights
What are the disease risks, burdens, and unmet needs of PH-ILD? What will be the growth opportunities across the 7MM with respect to the patient population pertaining to PH-ILD?
What is the historical and forecasted PH-ILD patient pool in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?
Out of the countries mentioned above, which country would have the highest diagnosed prevalent PH-ILD population during the forecast period (2025–2034)?
What factors are contributing to the growth of PH-ILD cases?
Reasons to Buy
The report will help develop business strategies by understanding the latest trends and changing disease dynamics driving the PH-ILD.
Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
The distribution of historical and current patient share is based on real-world prescription data in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
To understand the PH-ILD cases in varying geographies over the coming years.
To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis options.
Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.
Frequently Asked Questions
1. What is the forecast period covered in the report?
The PH-ILD epidemiology report for the 7MM covers the forecast period from 2025 to 2034, providing a projection of epidemiology dynamics and trends during this timeframe.
2. Out of all EU4 countries and the UK, which country had the highest population of PH-ILD cases in 2024?
The highest cases of PH-ILD were found in the UK among EU4 and the UK in 2024.
3. How is epidemiological data collected and analyzed for forecasting purposes?
Epidemiological data is collected through surveys, clinical studies, health records, and other sources. It is then analyzed to calculate disease rates, identify trends, and project future disease burdens using mathematical models.
4. Out of all 7MM countries, which country had the highest population of PH-ILD cases in 2024?
The highest cases of PH-ILD were found in the US among the 7MM in 2024.
DelveInsight research indicates that in 2024, there were around 180,000 diagnosed prevalent cases of PH-ILD across the 7MM, which are expected to increase by 2034.
In the US, there were over 80,000 diagnosed prevalent cases of PH-ILD in 2024, accounting for approximately 45% of all diagnosed cases across the 7MM.
The rise in PH-ILD cases in the 7MM is driven by improved diagnostic tools, and a growing aging population. Broader screening among patients with Interstitial Lung Diseases (ILD) and advancements in imaging and pulmonary testing also contribute. Additionally, evolving clinical guidelines promote earlier detection, leading to higher reported prevalence rates over time.
Japan accounted for 16% of the diagnosed PH-ILD cases across the 7MM. The number of cases is expected to rise due to the country's aging population, which increases the risk of ILD and related complications.
In Germany, PH-ILD prevalence was slightly higher in males with nearly 8,700 cases as compared to 6,300 females in 2024, with the gap expected to widen by 2034.
Early and accurate diagnosis of PH-ILD remains challenging due to overlapping symptoms with other respiratory conditions and the absence of specific diagnostic tools, often leading to delays in identification and increased risk of disease progression.
DelveInsight’s “Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) –Epidemiology Forecast – 2034” report delivers an in-depth understanding of PH-ILD, historical and forecasted epidemiology trends in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
The PH-ILD report focuses on the epidemiological landscape, providing detailed insights into current and forecasted diagnosed prevalence across the 7MM from 2020 to 2034. It highlights geographic variations, demographic trends, and factors influencing disease burden to support strategic planning and resource allocation.
Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Disease Understanding
Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Overview
PH-ILD is a chronic, progressive condition that develops as a complication of various ILDs, including idiopathic pulmonary fibrosis (IPF), connective tissue disease (CTD), and hypersensitivity pneumonitis. It is marked by elevated pressure in the pulmonary arteries due to lung scarring and vascular remodeling. This places increased strain on the heart and lungs, leading to symptoms such as worsening shortness of breath, fatigue, and reduced exercise capacity. Over time, these symptoms significantly limit daily activities and diminish quality of life. PH-ILD is often underdiagnosed or diagnosed late, as its symptoms overlap with those of the underlying ILD.
Further details related to country-based variations are provided in the report…
Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Diagnosis
Diagnosing PH-ILD is challenging due to overlapping symptom PH-ILD with underlying ILD. Suspicion should arise in ILD patients with unexplained worsening dyspnea or reduced exercise capacity. Key tools include echocardiography for initial screening and pulmonary function tests showing a disproportionate drop in Diffusing Capacity for Carbon Monoxide (DLCO). High-resolution Computed Tomography (CT) aids in assessing lung fibrosis, while right heart catheterization (RHC) remains the gold standard for confirming pulmonary hypertension. Early, accurate diagnosis through routine monitoring in high-risk ILD patients is crucial for timely intervention and improved outcomes.
Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Epidemiology
For the purpose of designing the patient-based model for PH-ILD, the PH-ILD epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by total diagnosed prevalent cases of ILD, type-specific diagnosed prevalent cases of ILD, type-specific diagnosed prevalent cases of PH-ILD, total diagnosed prevalent cases of PH-ILD, and gender-specific diagnosed prevalent cases of PH-ILD in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan from 2020 to 2034.
In 2024, approximately 1.1 million diagnosed prevalent cases of ILD were reported across the 7MM. This rising burden is largely attributed to improved disease recognition, broader use of high-resolution imaging, and increased awareness among physicians and specialists.
In the US, among the type-specific diagnosed prevalent cases of ILD, idiopathic pulmonary fibrosis (IPF)-associated ILD accounted for the highest number, with nearly 112,000 reported cases in 2024.
In the UK, among the type-specific diagnosed prevalent cases of PH-ILD, sarcoidosis-associated cases were the most common, with approximately 4,000 reported cases in 2024.
In 2024, nearly 70,000 people in the EU4 and UK were living with diagnosed PH-ILD, underscoring a substantial and growing regional disease burden.
In 2024, diagnosed PH-ILD prevalence showed a slightly higher burden in males, with approximately 42,000 cases compared to 39,000 in females in the US. This gender gap is expected to widen by 2034, highlighting potential differences in disease susceptibility or progression.
In 2024, IPF accounted for the largest share of PH-ILD cases in Japan at 21%, while hypersensitivity pneumonitis represented just 1%, underscoring notable variation in subtype distribution and the need for tailored diagnostic and treatment strategies.
In Japan, over 28,000 diagnosed prevalent cases of PH-ILD were reported in 2024, with the numbers projected to increase by 2034, indicating a rising disease burden.
KOL Views
To keep up with current innovation, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts contacted for insights on PH-ILD evolving disease landscape along with challenges related to accessibility, including Medical/scientific writers, Medical Professionals, Professors, Directors, and others.
DelveInsight’s analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Centers like the Baylor College of Medicine and Methodist Hospital, US; University of Minnesota, US; University of Freiburg, Germany; Hôpital St Louis, France; University of Siena, Italy; University of Valencia, Spain; University Forvie Site, UK; Jichi Medical University, Japan; and Chiba University, Japan; among others, were contacted. Their opinion helps understand and validate current disease prevalence, gender involved with the disease, diagnosis rate, and diagnostic criteria.
Physician’s View
As per the KOLs from the US, PH-ILD care faces significant challenges, as timely diagnosis remains limited despite rising prevalence. Overlapping symptoms with other ILDs often contribute to delayed recognition, resulting in patients being identified only at more advanced stages of the disease.
As per the KOLs from the Germany, PH-ILD is characterized by complex vascular remodeling and fibrotic processes, which contribute to disease progression and symptom severity. These underlying mechanisms highlight the need for deeper understanding and innovative approaches to better address the biological drivers of the condition.
As per the KOLs from Japan, The growing burden of PH-ILD, particularly among aging ILD populations, is compounded by the disease’s heterogeneity and complexity. The absence of standardized clinical approaches adds to the challenges, highlighting persistent gaps in real-world patient management and care strategies.
Scope of the Report
The report covers a segment of key events, an executive summary, and a descriptive overview of PH-ILD, explaining its causes, signs and symptom PH-ILD and pathogenesis.
Comprehensive insight into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and diagnostic guidelines have been provided.
The report provides an edge for understanding trends, expert insights/KOL views, and patient journeys in the 7MM.
A detailed review of current challenges in establishing the diagnosis.
Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Report Insights
Patient Population
Country-wise Epidemiology Distribution
Total Diagnosed Prevalent Cases of ILD
Type-specific Diagnosed Prevalent Cases of ILD
Type-specific Diagnosed Prevalent Cases of PH-ILD
Total Diagnosed Prevalent Cases of PH-ILD
Gender-specific Diagnosed Prevalent Cases of PH-ILD
Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Report Key Strengths
10 years Forecast
The 7MM Coverage
PH-ILD Epidemiology Segmentation
Key Questions
Epidemiology Insights
What are the disease risks, burdens, and unmet needs of PH-ILD? What will be the growth opportunities across the 7MM with respect to the patient population pertaining to PH-ILD?
What is the historical and forecasted PH-ILD patient pool in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?
Out of the countries mentioned above, which country would have the highest diagnosed prevalent PH-ILD population during the forecast period (2025–2034)?
What factors are contributing to the growth of PH-ILD cases?
Reasons to Buy
The report will help develop business strategies by understanding the latest trends and changing disease dynamics driving the PH-ILD.
Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
The distribution of historical and current patient share is based on real-world prescription data in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
To understand the PH-ILD cases in varying geographies over the coming years.
To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis options.
Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.
Frequently Asked Questions
1. What is the forecast period covered in the report?
The PH-ILD epidemiology report for the 7MM covers the forecast period from 2025 to 2034, providing a projection of epidemiology dynamics and trends during this timeframe.
2. Out of all EU4 countries and the UK, which country had the highest population of PH-ILD cases in 2024?
The highest cases of PH-ILD were found in the UK among EU4 and the UK in 2024.
3. How is epidemiological data collected and analyzed for forecasting purposes?
Epidemiological data is collected through surveys, clinical studies, health records, and other sources. It is then analyzed to calculate disease rates, identify trends, and project future disease burdens using mathematical models.
4. Out of all 7MM countries, which country had the highest population of PH-ILD cases in 2024?
The highest cases of PH-ILD were found in the US among the 7MM in 2024.
Table of Contents
95 Pages
- 1. Key Insights
- 2. Report Introduction
- 3. PH-ILD Epidemiology Overview at a Glance
- 3.1. Patient Share (%) Distribution of PH-ILD in 2024
- 3.2. Patient Share (%) Distribution of PH-ILD in 2034
- 4. Executive Summary
- 5. Disease Background and Overview
- 5.1. Introduction
- 5.2. Classification
- 5.3. Clinical Manifestations
- 5.4. Risk Factors
- 5.5. Pathogenesis
- 5.6. Recurrent PH-ILD
- 5.7. Biomarkers
- 5.8. Diagnosis
- 5.8.1. Differential Diagnosis
- 5.8.2. Diagnostic Algorithm
- 5.8.3. Diagnostic Guidelines and Recommendations
- 6. Methodology
- 7. Epidemiology and Patient Population
- 7.1. Key Findings
- 7.2. Assumptions and Rationale: The 7MM
- 7.2.1. Total Diagnosed Prevalent Cases of ILD
- 7.2.2. Type-specific Diagnosed Prevalent Cases of ILD
- 7.2.3. Type-specific Diagnosed Prevalent Cases of PH-ILD
- 7.2.4. Total Diagnosed Prevalent Cases of PH-ILD
- 7.2.5. Gender-specific Diagnosed Prevalent Cases of PH-ILD
- 7.3. Total Diagnosed Prevalent Cases of PH-ILD in the 7MM
- 7.4. The US
- 7.4.1. Total Diagnosed Prevalent Cases of ILD
- 7.4.2. Type-specific Diagnosed Prevalent Cases of ILD
- 7.4.3. Type-specific Diagnosed Prevalent Cases of PH-ILD
- 7.4.4. Total Diagnosed Prevalent Cases of PH-ILD
- 7.4.5. Gender-specific Diagnosed Prevalent Cases of PH-ILD
- 7.5. EU4 and the UK
- 7.5.1. Total Diagnosed Prevalent Cases of ILD
- 7.5.2. Type-specific Diagnosed Prevalent Cases of ILD
- 7.5.3. Type-specific Diagnosed Prevalent Cases of PH-ILD
- 7.5.4. Total Diagnosed Prevalent Cases of PH-ILD
- 7.5.5. Gender-specific Diagnosed Prevalent Cases of PH-ILD
- 7.6. Japan
- 7.6.1. Total Diagnosed Prevalent Cases of ILD
- 7.6.2. Type-specific Diagnosed Prevalent Cases of ILD
- 7.6.3. Type-specific Diagnosed Prevalent Cases of PH-ILD
- 7.6.4. Total Diagnosed Prevalent Cases of PH-ILD
- 7.6.5. Gender-specific Diagnosed Prevalent Cases of PH-ILD
- 8. Patient Journey
- 9. KOL Views
- 10. Appendix
- 10.1. Acronyms and Abbreviations
- 10.2. Bibliography
- 10.3. Report Methodology
- 11. DelveInsight Capabilities
- 12. Disclaimer
- 13. About DelveInsight
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
